TY - JOUR AU - Lipe, B. AU - Vukas, R. AU - Mikhael, J. PY - 2016 DA - 2016// TI - The role of maintenance therapy in multiple myeloma JO - Blood Cancer Journal VL - 6 UR - https://doi.org/10.1038/bcj.2016.89 DO - 10.1038/bcj.2016.89 ID - Lipe2016 ER - TY - JOUR AU - Michels, T. C. AU - Petersen, K. E. PY - 2017 DA - 2017// TI - Multiple myeloma: diagnosis and treatment JO - Am Fam Physician VL - 95 ID - Michels2017 ER - TY - JOUR AU - Kehrer, M. AU - Koob, S. AU - Strauss, A. AU - Wirtz, D. C. AU - Schmolders, J. PY - 2017 DA - 2017// TI - Multiple myeloma - current status in diagnostic testing and therapy JO - Zeitschrift fur Orthopadie und Unfallchirurgie VL - 155 UR - https://doi.org/10.1055/s-0043-110224 DO - 10.1055/s-0043-110224 ID - Kehrer2017 ER - TY - JOUR AU - Stegen, S. J. AU - Hamieh, M. AU - Sadelain, M. PY - 2015 DA - 2015// TI - The pharmacology of second-generation chimeric antigen receptors JO - Nat Rev Drug Discov VL - 14 UR - https://doi.org/10.1038/nrd4597 DO - 10.1038/nrd4597 ID - Stegen2015 ER - TY - JOUR AU - Jensen, M. C. AU - Riddell, S. R. PY - 2015 DA - 2015// TI - Designing chimeric antigen receptors to effectively and safely target tumors JO - Curr Opin Immunol VL - 33 UR - https://doi.org/10.1016/j.coi.2015.01.002 DO - 10.1016/j.coi.2015.01.002 ID - Jensen2015 ER - TY - JOUR AU - Ali, S. A. AU - Shi, V. AU - Maric, I. AU - Wang, M. AU - Stroncek, D. F. AU - Rose, J. J. PY - 2016 DA - 2016// TI - T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma JO - Blood. VL - 128 UR - https://doi.org/10.1182/blood-2016-04-711903 DO - 10.1182/blood-2016-04-711903 ID - Ali2016 ER - TY - JOUR AU - Garfall, A. L. AU - Maus, M. V. AU - Hwang, W. T. AU - Lacey, S. F. AU - Mahnke, Y. D. AU - Melenhorst, J. J. PY - 2015 DA - 2015// TI - Chimeric antigen receptor T cells against CD19 for multiple myeloma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504542 DO - 10.1056/NEJMoa1504542 ID - Garfall2015 ER - TY - JOUR AU - Brudno, J. N. AU - Maric, I. AU - Hartman, S. D. AU - Rose, J. J. AU - Wang, M. AU - Lam, N. PY - 2018 DA - 2018// TI - T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.77.8084 DO - 10.1200/JCO.2018.77.8084 ID - Brudno2018 ER - TY - JOUR AU - Zhao, W. -. H. AU - Liu, J. AU - Wang, B. -. Y. AU - Chen, Y. -. X. AU - Cao, X. -. M. AU - Yang, Y. PY - 2018 DA - 2018// TI - A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0681-6 DO - 10.1186/s13045-018-0681-6 ID - Zhao2018 ER - TY - JOUR AU - Melchor, L. AU - Brioli, A. AU - Wardell, C. P. AU - Murison, A. AU - Potter, N. E. AU - Kaiser, M. F. PY - 2014 DA - 2014// TI - Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma JO - Leukemia. VL - 28 UR - https://doi.org/10.1038/leu.2014.13 DO - 10.1038/leu.2014.13 ID - Melchor2014 ER - TY - JOUR AU - Hajek, R. AU - Okubote, S. A. AU - Svachova, H. PY - 2013 DA - 2013// TI - Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma JO - Br J Haematol VL - 163 UR - https://doi.org/10.1111/bjh.12563 DO - 10.1111/bjh.12563 ID - Hajek2013 ER - TY - JOUR AU - Bolli, N. AU - Avet-Loiseau, H. AU - Wedge, D. C. AU - Loo, P. AU - Alexandrov, L. B. AU - Martincorena, I. PY - 2014 DA - 2014// TI - Heterogeneity of genomic evolution and mutational profiles in multiple myeloma JO - Nat Commun VL - 5 UR - https://doi.org/10.1038/ncomms3997 DO - 10.1038/ncomms3997 ID - Bolli2014 ER - TY - JOUR AU - Paino, T. AU - Paiva, B. AU - Sayagues, J. M. AU - Mota, I. AU - Carvalheiro, T. AU - Corchete, L. A. PY - 2015 DA - 2015// TI - Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential JO - Leukemia. VL - 29 UR - https://doi.org/10.1038/leu.2014.321 DO - 10.1038/leu.2014.321 ID - Paino2015 ER - TY - JOUR AU - Tai, Y. T. AU - Anderson, K. C. PY - 2015 DA - 2015// TI - Targeting B-cell maturation antigen in multiple myeloma JO - Immunotherapy. VL - 7 UR - https://doi.org/10.2217/imt.15.77 DO - 10.2217/imt.15.77 ID - Tai2015 ER - TY - JOUR AU - Tai, Y. T. AU - Acharya, C. AU - An, G. AU - Moschetta, M. AU - Zhong, M. Y. AU - Feng, X. PY - 2016 DA - 2016// TI - APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment JO - Blood. VL - 127 UR - https://doi.org/10.1182/blood-2016-01-691162 DO - 10.1182/blood-2016-01-691162 ID - Tai2016 ER - TY - JOUR AU - Lee, L. AU - Bounds, D. AU - Paterson, J. AU - Herledan, G. AU - Sully, K. AU - Seestaller-Wehr, L. M. PY - 2016 DA - 2016// TI - Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma JO - Br J Haematol VL - 174 UR - https://doi.org/10.1111/bjh.14145 DO - 10.1111/bjh.14145 ID - Lee2016 ER - TY - JOUR AU - Sanchez, E. AU - Gillespie, A. AU - Tang, G. AU - Ferros, M. AU - Harutyunyan, N. M. AU - Vardanyan, S. PY - 2016 DA - 2016// TI - Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2224 DO - 10.1158/1078-0432.CCR-15-2224 ID - Sanchez2016 ER - TY - JOUR AU - Topp, M. S. AU - Duell, J. AU - Zugmaier, G. AU - Attal, M. AU - Moreau, P. AU - Langer, C. PY - 2018 DA - 2018// TI - Treatment with AMG 420, an anti-B-cell maturation antigen (BCMA) bispecific T-cell engager antibody construct, induces minimal residual disease (MRD) negative complete responses in relapsed and/or refractory (R/R) multiple myeloma (MM) patients: results of a first-in-human (FIH) phase I dose escalation study JO - Blood. VL - 132 UR - https://doi.org/10.1182/blood-2018-99-109769 DO - 10.1182/blood-2018-99-109769 ID - Topp2018 ER - TY - JOUR AU - Trudel, S. AU - Lendvai, N. AU - Popat, R. AU - Voorhees, P. M. AU - Reeves, B. AU - Libby, E. N. PY - 2018 DA - 2018// TI - Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial JO - The Lancet Oncology VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30576-X DO - 10.1016/S1470-2045(18)30576-X ID - Trudel2018 ER - TY - JOUR AU - Raje, N. AU - Berdeja, J. AU - Lin, Y. AU - Siegel, D. PY - 2019 DA - 2019// TI - Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1817226 DO - 10.1056/NEJMoa1817226 ID - Raje2019 ER - TY - JOUR AU - Friedman, K. M. AU - Garrett, T. E. AU - Evans, J. W. AU - Horton, H. M. AU - Latimer, H. J. AU - Seidel, S. L. PY - 2018 DA - 2018// TI - Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells JO - Hum Gene Ther VL - 29 UR - https://doi.org/10.1089/hum.2018.001 DO - 10.1089/hum.2018.001 ID - Friedman2018 ER - TY - JOUR AU - Berdeja, J. G. AU - Lin, Y. AU - Raje, N. AU - Munshi, N. AU - Siegel, D. AU - Liedtke, M. PY - 2017 DA - 2017// TI - Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-Bcma CAR T cell therapy JO - Blood. VL - 130 ID - Berdeja2017 ER - TY - STD TI - Shah N, Alsina M, Siegel DS, Jagannath S, Madduri D, Kaufman JL, et al. Initial results from a phase 1 clinical study of bb21217, a next-generation anti Bcma CAR T therapy. Blood. 2018;https://doi.org/10.1182/blood-2018-99-116953. ID - ref23 ER - TY - JOUR AU - Xu, J. AU - Chen, L. J. AU - Yang, S. S. AU - Sun, Y. AU - Wu, W. AU - Liu, Y. F. PY - 2019 DA - 2019// TI - Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma JO - Proc Natl Acad Sci U S A VL - 116 UR - https://doi.org/10.1073/pnas.1819745116 DO - 10.1073/pnas.1819745116 ID - Xu2019 ER - TY - STD TI - Gregory T, Cohen AD, Costello CL, Ali SA, Berdeja JG, Ostertag EM, et al. Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM). Blood. 2018;https://doi.org/10.1182/blood-2018-99-111419. ID - ref25 ER - TY - JOUR AU - Gregory, T. K. AU - Berdeja, J. G. AU - Patel, K. K. AU - Ali, S. A. AU - Cohen, A. D. AU - Costello, C. PY - 2018 DA - 2018// TI - Abstract CT130: clinical trial of P-BCMA-101 T stem cell memory (Tscm) CAR-T cells in relapsed/refractory (r/r) multiple myeloma (MM) JO - Cancer Res VL - 78 ID - Gregory2018 ER - TY - STD TI - Mailankody S, Htut M, Lee KP, Bensinger W, Devries T, Piasecki J, et al. JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE). Blood. 2018;https://doi.org/10.1182/blood-2018-99-113548. ID - ref27 ER - TY - STD TI - Jiang S, Jin J, Hao S, Yang M, Chen L, Ruan H, et al. Low dose of human scFv-derived BCMA-targeted CAR-T cells achieved fast response and high complete remission in patients with relapsed/refractory multiple myeloma. Blood. 2018;132(Suppl 1):960-60. ID - ref28 ER - TY - STD TI - Mailankody S, Ghosh A, Staehr M, Purdon TJ, Roshal M, Halton E, et al. Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a phase I clinical trial. Blood. 2018;132(Suppl 1):959-59. ID - ref29 ER - TY - JOUR AU - Li, C. AU - Wang, Q. AU - Zhu, H. AU - Mao, X. AU - Wang, Y. AU - Zhang, Y. PY - 2018 DA - 2018// TI - T cells expressing anti B-cell maturation antigen chimeric antigen receptors for plasma cell malignancies JO - Blood. VL - 132 UR - https://doi.org/10.1182/blood-2018-99-116898 DO - 10.1182/blood-2018-99-116898 ID - Li2018 ER - TY - JOUR AU - Xu, J. AU - Wang, Q. AU - Xu, H. AU - Gu, C. AU - Jiang, L. AU - Wang, J. PY - 2018 DA - 2018// TI - Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0672-7 DO - 10.1186/s13045-018-0672-7 ID - Xu2018 ER - TY - STD TI - Li C ZJ, Wang J, Hu G, Du A, Zhou X, Meng L, Hong Z, Chen L, Mao X. Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma. J Clin Oncol 2019;37:8013-13. ID - ref32 ER - TY - JOUR AU - Cohen, A. D. AU - Garfall, A. L. AU - Stadtmauer, E. A. AU - Melenhorst, J. J. AU - Lacey, S. F. AU - Lancaster, E. PY - 2019 DA - 2019// TI - B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma JO - J Clin Invest VL - 129 UR - https://doi.org/10.1172/JCI126397 DO - 10.1172/JCI126397 ID - Cohen2019 ER - TY - STD TI - Liu Y, Chen Z, Fang H, Wei R, Yu K, Jiang S, et al. Durable remission achieved from Bcma-directed CAR-T Therapy against relapsed or refractory multiple myeloma. Blood. 2018;132(Suppl 1):956-56. ID - ref34 ER - TY - STD TI - Han L, Gao Q, Zhou K, Yin Q, Fang B, Zhou J, et al. Development and evaluation of CART targeting Bcma with humanized alpaca-derived single-domain antibody as antigen recognition domain. Blood. 2018;132(Suppl 1):1976-76. ID - ref35 ER - TY - STD TI - Yan L, Shang J, Kang L, Shi X, Zhou J, Jin S, et al. Combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for RRMM: initial safety and efficacy report from a clinical pilot study. Blood. 2017;130(Suppl 1):506-06. ID - ref36 ER - TY - STD TI - Shi X, Yan L, Shang J, Qu S, Kang L, Zhou J, et al. Tandom autologous transplantation and combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for high risk MM: initial safety and efficacy report from a clinical pilot study. Blood. 2018;https://doi.org/10.1182/blood-2018-99-117964. ID - ref37 ER - TY - JOUR AU - Wang, K. AU - Wei, G. AU - Liu, D. PY - 2012 DA - 2012// TI - CD19: a biomarker for B cell development, lymphoma diagnosis and therapy JO - Experimental Hematology & Oncology VL - 1 UR - https://doi.org/10.1186/2162-3619-1-36 DO - 10.1186/2162-3619-1-36 ID - Wang2012 ER - TY - JOUR AU - Johnsen, H. E. AU - Bogsted, M. AU - Schmitz, A. AU - Bodker, J. S. AU - El-Galaly, T. C. AU - Johansen, P. PY - 2016 DA - 2016// TI - The myeloma stem cell concept, revisited: from phenomenology to operational terms JO - Haematologica. VL - 101 UR - https://doi.org/10.3324/haematol.2015.138826 DO - 10.3324/haematol.2015.138826 ID - Johnsen2016 ER - TY - JOUR AU - Franqui-Machin, R. AU - Wendlandt, E. B. AU - Janz, S. AU - Zhan, F. AU - Tricot, G. PY - 2015 DA - 2015// TI - Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.5800 DO - 10.18632/oncotarget.5800 ID - Franqui-Machin2015 ER - TY - STD TI - Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight. 2018;https://doi.org/10.1172/jci.insight.120505. ID - ref41 ER - TY - JOUR AU - Yan, Z. AU - Cao, J. AU - Cheng, H. AU - Qiao, J. AU - Zhang, H. AU - Wang, Y. PY - 2019 DA - 2019// TI - A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial JO - The Lancet Haematology VL - 6 UR - https://doi.org/10.1016/S2352-3026(19)30115-2 DO - 10.1016/S2352-3026(19)30115-2 ID - Yan2019 ER - TY - JOUR AU - Schuberth, P. C. AU - Jakka, G. AU - Jensen, S. M. AU - Wadle, A. AU - Gautschi, F. AU - Haley, D. PY - 2013 DA - 2013// TI - Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma JO - Gene Ther VL - 20 UR - https://doi.org/10.1038/gt.2012.48 DO - 10.1038/gt.2012.48 ID - Schuberth2013 ER - TY - JOUR AU - Rapoport, A. P. AU - Stadtmauer, E. A. AU - Binder-Scholl, G. K. AU - Goloubeva, O. AU - Vogl, D. T. AU - Lacey, S. F. PY - 2015 DA - 2015// TI - NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3910 DO - 10.1038/nm.3910 ID - Rapoport2015 ER - TY - JOUR AU - Stadtmauer, E. A. AU - Faitg, T. H. AU - Lowther, D. E. AU - Badros, A. Z. PY - 2019 DA - 2019// TI - Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma JO - Blood Advances VL - 3 UR - https://doi.org/10.1182/bloodadvances.2019000194 DO - 10.1182/bloodadvances.2019000194 ID - Stadtmauer2019 ER - TY - JOUR AU - Mastaglio, S. AU - Genovese, P. AU - Magnani, Z. AU - Ruggiero, E. AU - Landoni, E. AU - Camisa, B. PY - 2017 DA - 2017// TI - NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease JO - Blood. VL - 130 UR - https://doi.org/10.1182/blood-2016-08-732636 DO - 10.1182/blood-2016-08-732636 ID - Mastaglio2017 ER - TY - JOUR AU - Ramos, C. A. AU - Savoldo, B. AU - Torrano, V. AU - Ballard, B. AU - Zhang, H. AU - Dakhova, O. PY - 2016 DA - 2016// TI - Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains JO - J Clin Invest VL - 126 UR - https://doi.org/10.1172/JCI86000 DO - 10.1172/JCI86000 ID - Ramos2016 ER - TY - JOUR AU - Hutchinson, A. T. AU - Jones, D. R. AU - Raison, R. L. PY - 2015 DA - 2015// TI - Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma JO - Mol Immunol VL - 67 UR - https://doi.org/10.1016/j.molimm.2015.04.013 DO - 10.1016/j.molimm.2015.04.013 ID - Hutchinson2015 ER - TY - JOUR AU - Liebisch, P. AU - Eppinger, S. AU - Schopflin, C. AU - Stehle, G. AU - Munzert, G. AU - Dohner, H. PY - 2005 DA - 2005// TI - CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q JO - Haematologica. VL - 90 ID - Liebisch2005 ER - TY - JOUR AU - Tijink, B. M. AU - Buter, J. AU - Bree, R. AU - Giaccone, G. AU - Lang, M. S. AU - Staab, A. PY - 2006 DA - 2006// TI - A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0910 DO - 10.1158/1078-0432.CCR-06-0910 ID - Tijink2006 ER - TY - JOUR AU - Casucci, M. AU - Nicolis di Robilant, B. AU - Falcone, L. AU - Camisa, B. AU - Norelli, M. AU - Genovese, P. PY - 2013 DA - 2013// TI - CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma JO - Blood. VL - 122 UR - https://doi.org/10.1182/blood-2013-04-493361 DO - 10.1182/blood-2013-04-493361 ID - Casucci2013 ER - TY - JOUR AU - Camp, B. AU - Durie, B. G. AU - Spier, C. AU - Waele, M. AU - Riet, I. AU - Vela, E. PY - 1990 DA - 1990// TI - Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19) JO - Blood. VL - 76 UR - https://doi.org/10.1182/blood.V76.2.377.377 DO - 10.1182/blood.V76.2.377.377 ID - Camp1990 ER - TY - JOUR AU - Tassone, P. AU - Gozzini, A. AU - Goldmacher, V. AU - Shammas, M. A. AU - Whiteman, K. R. AU - Carrasco, D. R. PY - 2004 DA - 2004// TI - In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-0142 DO - 10.1158/0008-5472.CAN-04-0142 ID - Tassone2004 ER - TY - STD TI - Berdeja JG. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. Front Biosci (Landmark edition). 2014;19:163-170. ID - ref54 ER - TY - STD TI - Benjamin R CM, Gunset G, Sadelain M. . CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma. Cancer Res 2012;72(8 Supplement):3499-99. ID - ref55 ER - TY - JOUR AU - McEarchern, J. A. AU - Smith, L. M. AU - McDonagh, C. F. AU - Klussman, K. AU - Gordon, K. A. AU - Morris-Tilden, C. A. PY - 2008 DA - 2008// TI - Preclinical characterization of SGN-70, a humanized antibody directed against CD70 JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-08-0493 DO - 10.1158/1078-0432.CCR-08-0493 ID - McEarchern2008 ER - TY - JOUR AU - Tannir, N. M. AU - Forero-Torres, A. AU - Ramchandren, R. AU - Pal, S. K. AU - Ansell, S. M. AU - Infante, J. R. PY - 2014 DA - 2014// TI - Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma JO - Investig New Drugs VL - 32 UR - https://doi.org/10.1007/s10637-014-0151-0 DO - 10.1007/s10637-014-0151-0 ID - Tannir2014 ER - TY - JOUR AU - Owonikoko, T. K. AU - Hussain, A. AU - Stadler, W. M. AU - Smith, D. C. AU - Kluger, H. AU - Molina, A. M. PY - 2016 DA - 2016// TI - First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70 JO - Cancer Chemother Pharmacol VL - 77 UR - https://doi.org/10.1007/s00280-015-2909-2 DO - 10.1007/s00280-015-2909-2 ID - Owonikoko2016 ER - TY - JOUR AU - Wang, Q. J. AU - Yu, Z. AU - Hanada, K. I. AU - Patel, K. AU - Kleiner, D. AU - Restifo, N. P. PY - 2017 DA - 2017// TI - Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-1421 DO - 10.1158/1078-0432.CCR-16-1421 ID - Wang2017 ER - TY - JOUR AU - Ge, H. AU - Mu, L. AU - Jin, L. AU - Yang, C. AU - Chang, Y. E. AU - Long, Y. PY - 2017 DA - 2017// TI - Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM JO - Int J Cancer VL - 141 UR - https://doi.org/10.1002/ijc.30830 DO - 10.1002/ijc.30830 ID - Ge2017 ER - TY - JOUR AU - Jin, L. AU - Ge, H. AU - Long, Y. AU - Yang, C. AU - Chang, Y. E. AU - Mu, L. PY - 2018 DA - 2018// TI - CD70, a novel target of CAR T-cell therapy for gliomas JO - Neuro-oncology. VL - 20 UR - https://doi.org/10.1093/neuonc/nox116 DO - 10.1093/neuonc/nox116 ID - Jin2018 ER - TY - JOUR AU - Fernandez, J. E. AU - Deaglio, S. AU - Donati, D. AU - Beusan, I. S. AU - Corno, F. AU - Aranega, A. PY - 1998 DA - 1998// TI - Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues JO - J Biol Regul Homeost Agents VL - 12 ID - Fernandez1998 ER - TY - STD TI - de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (Baltimore, MD: 1950). 2011;186(3):1840-1848. ID - ref63 ER - TY - STD TI - Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet (London, England). 2016;387(10027):1551-1560. ID - ref64 ER - TY - JOUR AU - Martin, T. AU - Baz, R. AU - Benson, D. M. AU - Lendvai, N. AU - Wolf, J. AU - Munster, P. PY - 2017 DA - 2017// TI - A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2016-09-740787 DO - 10.1182/blood-2016-09-740787 ID - Martin2017 ER - TY - JOUR AU - Drent, E. AU - Themeli, M. AU - Poels, R. AU - Jong-Korlaar, R. AU - Yuan, H. AU - Bruijn, J. PY - 2017 DA - 2017// TI - A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization JO - Mol Ther VL - 25 UR - https://doi.org/10.1016/j.ymthe.2017.04.024 DO - 10.1016/j.ymthe.2017.04.024 ID - Drent2017 ER - TY - JOUR AU - Drent, E. AU - Groen, R. W. AU - Noort, W. A. AU - Themeli, M. AU - Lammerts van Bueren, J. J. AU - Parren, P. W. PY - 2016 DA - 2016// TI - Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma JO - Haematologica. VL - 101 UR - https://doi.org/10.3324/haematol.2015.137620 DO - 10.3324/haematol.2015.137620 ID - Drent2016 ER - TY - JOUR AU - Sanderson, R. D. AU - Turnbull, J. E. AU - Gallagher, J. T. AU - Lander, A. D. PY - 1994 DA - 1994// TI - Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior JO - J Biol Chem VL - 269 ID - Sanderson1994 ER - TY - JOUR AU - Wijdenes, J. AU - Vooijs, W. C. AU - Clement, C. AU - Post, J. AU - Morard, F. AU - Vita, N. PY - 1996 DA - 1996// TI - A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1 JO - Br J Haematol VL - 94 UR - https://doi.org/10.1046/j.1365-2141.1996.d01-1811.x DO - 10.1046/j.1365-2141.1996.d01-1811.x ID - Wijdenes1996 ER - TY - JOUR AU - Kambham, N. AU - Kong, C. AU - Longacre, T. A. AU - Natkunam, Y. PY - 2005 DA - 2005// TI - Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases JO - Applied Immunohistochemistry & Molecular Morphology: AIMM VL - 13 UR - https://doi.org/10.1097/01.pai.0000159773.50905.7b DO - 10.1097/01.pai.0000159773.50905.7b ID - Kambham2005 ER - TY - JOUR AU - Jagannath, S. AU - Chanan-Khan, A. AU - Heffner, L. T. AU - Avigan, D. AU - Zimmerman, T. M. AU - Lonial, S. PY - 2011 DA - 2011// TI - BT062, An antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma JO - Blood. VL - 118 UR - https://doi.org/10.1182/blood.V118.21.305.305 DO - 10.1182/blood.V118.21.305.305 ID - Jagannath2011 ER - TY - JOUR AU - Kelly, K. R. AU - Siegel, D. S. AU - Chanan-Khan, A. A. AU - Somlo, G. AU - Heffner, L. T. AU - Jagannath, S. PY - 2016 DA - 2016// TI - Indatuximab ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: clinical activity in patients with relapsed/refractory multiple myeloma JO - Blood. VL - 128 UR - https://doi.org/10.1182/blood.V128.22.4486.4486 DO - 10.1182/blood.V128.22.4486.4486 ID - Kelly2016 ER - TY - JOUR AU - Bo, G. AU - Mei Xia, C. AU - Qing Wang, H. AU - Hui, F. AU - Han Ren, D. AU - Wen Ying, Z. PY - 2016 DA - 2016// TI - CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma JO - Journal of Cellular Immunotherapy VL - 2 UR - https://doi.org/10.1016/j.jocit.2014.11.001 DO - 10.1016/j.jocit.2014.11.001 ID - Bo2016 ER - TY - JOUR AU - Jung, O. AU - Trapp-Stamborski, V. AU - Purushothaman, A. AU - Jin, H. AU - Wang, H. AU - Sanderson, R. D. PY - 2016 DA - 2016// TI - Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins JO - Oncogenesis. VL - 5 UR - https://doi.org/10.1038/oncsis.2016.5 DO - 10.1038/oncsis.2016.5 ID - Jung2016 ER - TY - JOUR AU - Hsi, E. D. AU - Steinle, R. AU - Balasa, B. AU - Szmania, S. AU - Draksharapu, A. AU - Shum, B. P. PY - 2008 DA - 2008// TI - CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-4246 DO - 10.1158/1078-0432.CCR-07-4246 ID - Hsi2008 ER - TY - JOUR AU - Chu, J. AU - He, S. AU - Deng, Y. AU - Zhang, J. AU - Peng, Y. AU - Hughes, T. PY - 2014 DA - 2014// TI - Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2510 DO - 10.1158/1078-0432.CCR-13-2510 ID - Chu2014 ER - TY - JOUR AU - Gogishvili, T. AU - Danhof, S. AU - Prommersberger, S. AU - Rydzek, J. AU - Schreder, M. AU - Brede, C. PY - 2017 DA - 2017// TI - SLAMF7-CAR T-cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes JO - Blood. VL - 130 UR - https://doi.org/10.1182/blood-2017-04-778423 DO - 10.1182/blood-2017-04-778423 ID - Gogishvili2017 ER - TY - JOUR AU - Veillette, A. AU - Guo, H. PY - 2013 DA - 2013// TI - CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma JO - Crit Rev Oncol Hematol VL - 88 UR - https://doi.org/10.1016/j.critrevonc.2013.04.003 DO - 10.1016/j.critrevonc.2013.04.003 ID - Veillette2013 ER - TY - JOUR AU - Friend, R. AU - Bhutani, M. AU - Voorhees, P. M. AU - Usmani, S. Z. PY - 2017 DA - 2017// TI - Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma JO - Drug Design, Development and Therapy VL - 11 UR - https://doi.org/10.2147/DDDT.S98053 DO - 10.2147/DDDT.S98053 ID - Friend2017 ER - TY - STD TI - Mathur R, Zhang Z, He J, Galetto R, Gouble A, Chion-Sotinel I, et al. Abstract PR01: targeting multiple myeloma with universal SLAMF7-specific CAR T-cells. Cancer Immunology Research. https://doi.org/10.1158/2326-6074. ID - ref80 ER - TY - JOUR AU - Brauner-Osborne, H. AU - Jensen, A. A. AU - Sheppard, P. O. AU - Brodin, B. AU - Krogsgaard-Larsen, P. AU - O’Hara, P. PY - 2001 DA - 2001// TI - Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D JO - Biochim Biophys Acta VL - 1518 UR - https://doi.org/10.1016/S0167-4781(01)00197-X DO - 10.1016/S0167-4781(01)00197-X ID - Brauner-Osborne2001 ER - TY - STD TI - Cohen Y, Gutwein O, Garach-Jehoshua O, Bar-Haim A, Kornberg A. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology (Amsterdam, Netherlands). 2013;18(6):348-351. ID - ref82 ER - TY - JOUR AU - Bam, R. AU - Li, X. AU - Khan, S. AU - Ling, W. AU - Randal, S. S. AU - Yaccoby, S. PY - 2013 DA - 2013// TI - GPRC5D Is a cell surface plasma cell marker whose expression is high in myeloma cells and reduced following coculture with osteoclasts JO - Blood. VL - 122 UR - https://doi.org/10.1182/blood.V122.21.3099.3099 DO - 10.1182/blood.V122.21.3099.3099 ID - Bam2013 ER - TY - JOUR AU - Frigyesi, I. AU - Adolfsson, J. AU - Ali, M. AU - Kronborg Christophersen, M. AU - Johnsson, E. AU - Turesson, I. PY - 2014 DA - 2014// TI - Robust isolation of malignant plasma cells in multiple myeloma JO - Blood. VL - 123 UR - https://doi.org/10.1182/blood-2013-09-529800 DO - 10.1182/blood-2013-09-529800 ID - Frigyesi2014 ER - TY - STD TI - Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long T, et al. CAR T cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D), a novel target for the immunotherapy of multiple myeloma. Blood. 2018;https://doi.org/10.1182/blood-2018-99-110471. ID - ref85 ER - TY - JOUR AU - Baumeister, S. H. AU - Murad, J. AU - Werner, L. AU - Daley, H. AU - Trebeden-Negre, H. AU - Gicobi, J. K. PY - 2019 DA - 2019// TI - Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma JO - Cancer Immunology Research VL - 7 UR - https://doi.org/10.1158/2326-6066.CIR-18-0307 DO - 10.1158/2326-6066.CIR-18-0307 ID - Baumeister2019 ER - TY - JOUR AU - Giavridis, T. AU - Stegen, S. J. C. AU - Eyquem, J. AU - Hamieh, M. AU - Piersigilli, A. AU - Sadelain, M. PY - 2018 DA - 2018// TI - CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0041-7 DO - 10.1038/s41591-018-0041-7 ID - Giavridis2018 ER - TY - JOUR AU - Davila, M. L. AU - Riviere, I. AU - Wang, X. AU - Bartido, S. AU - Park, J. AU - Curran, K. PY - 2014 DA - 2014// TI - Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia JO - Sci Transl Med VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008226 DO - 10.1126/scitranslmed.3008226 ID - Davila2014 ER - TY - STD TI - Sterner RM, Sakemura R, Yang N, Cox MJ, Khadka RH, Forsman CL, et al. GM-CSF blockade during chimeric antigen receptor T cell therapy reduces cytokine release syndrome and neurotoxicity and may enhance their effector functions. Blood. 2018;https://doi.org/10.1182/blood-2018-99-111766. ID - ref89 ER - TY - JOUR AU - Pule, M. A. AU - Straathof, K. C. AU - Dotti, G. AU - Heslop, H. E. AU - Rooney, C. M. AU - Brenner, M. K. PY - 2005 DA - 2005// TI - A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells JO - Mol Ther VL - 12 UR - https://doi.org/10.1016/j.ymthe.2005.04.016 DO - 10.1016/j.ymthe.2005.04.016 ID - Pule2005 ER - TY - JOUR AU - Straathof, K. C. AU - Pule, M. A. AU - Yotnda, P. AU - Dotti, G. AU - Vanin, E. F. AU - Brenner, M. K. PY - 2005 DA - 2005// TI - An inducible caspase 9 safety switch for T-cell therapy JO - Blood. VL - 105 UR - https://doi.org/10.1182/blood-2004-11-4564 DO - 10.1182/blood-2004-11-4564 ID - Straathof2005 ER - TY - STD TI - Oldham RAA, Felizardo T, Zhu N, Fowler DH, Medin JA. CAR-modified Th1/Tc1-polarized T-Rapa cells dissociate inflammatory cytokine secretion from anti-tumor cytotoxicity. Blood. 2018;https://doi.org/10.1182/blood-2018-99-113642. ID - ref92 ER - TY - STD TI - Rajavel S, Ito CE, Abe K, Guerrero V, Uenishi GI, Scharenberg AM, et al. Chemically controlled, immunosuppression-resistant, anti-Bcma CAR-T cells for treatment of antibody-mediated autoimmunity. Blood. 2018;https://doi.org/10.1182/blood-2018-99-117630. ID - ref93 ER - TY - STD TI - Mestermann K, Rydzek J, Silke F, Nerreter T, Andreas M, Einsele H, et al. A novel pharmacologic ‘remote control’ to steer CAR-T cell function in vivo. Blood. 2018;https://doi.org/10.1182/blood-2018-99-118626. ID - ref94 ER - TY - JOUR AU - Smith, E. L. AU - Staehr, M. AU - Masakayan, R. AU - Tatake, I. J. AU - Purdon, T. J. AU - Wang, X. PY - 2018 DA - 2018// TI - Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector JO - Mol Ther VL - 26 UR - https://doi.org/10.1016/j.ymthe.2018.03.016 DO - 10.1016/j.ymthe.2018.03.016 ID - Smith2018 ER - TY - JOUR AU - Chong, E. A. AU - Melenhorst, J. J. AU - Lacey, S. F. AU - Ambrose, D. E. AU - Gonzalez, V. AU - Levine, B. L. PY - 2017 DA - 2017// TI - PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2016-09-738245 DO - 10.1182/blood-2016-09-738245 ID - Chong2017 ER - TY - STD TI - Bernabei L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, et al. PD-1 inhibitor combinations as salvage therapy for relapsed/refractory multiple myeloma (MM) patients progressing after Bcma-directed CAR T cells. Blood. 2018;https://doi.org/10.1182/blood-2018-99-119514. ID - ref97 ER - TY - STD TI - Pearl J, Urnov FD, Stamatoyannopoulos JA. Potent and timed epigenetic repression of PD-1 in human T cells. Blood. 2018;https://doi.org/10.1182/blood-2018-99-119011. ID - ref98 ER - TY - STD TI - McCauley S, Verma R, Oft M. Pegilodecakin, a Pegylated human IL-10 (AM0010), enhances the cytotoxicity of CAR-T cells in vitro and in vivo. Blood. 2018;https://doi.org/10.1182/blood-2018-99-119359. ID - ref99 ER - TY - STD TI - Cohen AD, Melenhorst JJ, Garfall AL, Lacey SF, Davis M, Vogl DT, et al. Predictors of T cell expansion and clinical responses following B-cell maturation antigen-specific chimeric antigen receptor T cell therapy (CART-BCMA) for relapsed/refractory multiple myeloma (MM). Blood. 2018;132(Suppl 1):1974-74. ID - ref100 ER - TY - STD TI - Dancy E, Garfall AL, Cohen AD, Fraietta JA, Davis M, Levine BL, et al. Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma. Blood. 2018;https://doi.org/10.1182/blood-2018-99-115319. ID - ref101 ER -